TheProfitWatch

AUPH - Aurinia Pharmaceuticals Inc

Day 1m 10m 60m PreMarket Market AfterHours Gap
11.23 0.24 (2.14%) --- --- --- 0.0 (0.0%) 0.23 (2.05%) 0.13 (1.21%) 0.13 (1.21%)

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Category: PHARMACEUTICAL PREPARATIONS
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
0.16
Diluted EPS:
0.16
Basic P/E:
71.6875
Diluted P/E:
71.6875
RSI(14) 1m:
69.57
VWAP:
11.46
RVol:
0.3891

Events

Period Kind Movement Occurred At

Related News